EPISODE · Feb 24, 2025 · 23 MIN
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
from BiotechTV - News · host BiotechTV
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
Embed this episode
Ready to play
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
0:00
23:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 23 minutes long.
When was this BiotechTV - News episode published?
This episode was published on February 24, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!